Modular designs fit the need to expand vaccine production capacity.

Flexible Vaccine Manufacturing

With vaccine distribution underway, temperature and data control are essential.

Preparing for the Unexpected

Biopharma must deliver on COVID-19 vaccines and other promising therapies.

A “New Normal” for 2021?

Suppliers prepare to meet the packaging COVID-19 demands. 

Is the Packaging Supply Chain Ready?

UK businesses must understand the value of innovation.

The Key for COVID-19 Recovery

Topic

Articles

With funding from the federal government, Merck will expand capacity to produce J&J’s COVID-19 vaccine.

Merck to Manufacture J&J Vaccine

Cynthia A. Challener is a contributing editor to Pharmaceutical Technology.

In a pandemic, genetic vaccines offer several advantages over traditional approaches.

Genetic Vaccine Platforms Demonstrate Their Potential

AstraZeneca has announced that the mass rollout of its COVID-19 vaccine has begun via the COVAX initiative. 

AstraZeneca Progresses Rollout of COVID-19 Vaccine to Low- and Middle-Income Countries

RDIF has announced that the Sputnik V vaccine for COVID-19 has been approved in Slovakia under the emergency use authorization procedure.

Slovakia Approves Sputnik V Vaccine

Pharmaceutical laboratories must work to maintain lab data integrity practices as the pandemic surges on and cybersecurity risks increase. 


Pandemic Spurs Cybersecurity Risks  in Laboratories 

Editor of Pharmaceutical Technology Europe

The rapid and efficient delivery of innovative treatments through the COVID-19 pandemic has demonstrated the value of collaborations within the bio/pharma industry.

Demonstrating the Value of Collaboration

Rita Peters is editorial director of Pharmaceutical Technology, Pharmaceutical Technology Europe, and BioPharm International.

Bio/pharma works hard today to change the calendar to tomorrow.

Fighting Through This Slow Season of Change

Distribution of the first one-dose vaccine for COVID-19 to start in early March.

J&J Vaccine Approved for Emergency Use

Jill Wechsler is Pharmaceutical Technology's Washington Editor, jillwechsler7@gmail.com.

To prevent future production delays of critical products, the Biden administration is examining supply chain vulnerabilities for pharmaceutical ingredients as part of a longer-range consideration of products important to public health. 

COVID-19 Vaccine Makers Overcome Challenges to Ramp Up Production

EMA's CHMP has started a rolling review of regdanvimab (CT-P59), which is a monoclonal antibody being developed by Celltrion for the treatment of COVID-19.

COVID-19 Update

Flexible Vaccine Manufacturing

Preparing for the Unexpected

A “New Normal” for 2021?

Is the Packaging Supply Chain Ready?

The Key for COVID-19 Recovery